Korro Bio shareholder proposes $165K share sale

Available on EDGAR 11/12/2026 - 05:10 PM EST Accepted by SEC EDGAR 11/12/2026 - 05:09 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Korro Bio, Inc. (KRRO) shareholder Atlas Venture Opportunity Fund II, L.P. reports a proposed sale of 11,431 common shares, with an aggregate market value of $164,720.71 and an approximate sale date of November 12, 2026.

The fund acquired the shares from Korro Bio in a private placement for cash on April 22, 2024. The notice also reports prior sales by Atlas Venture Opportunity Fund II and Atlas Venture Fund XI, L.P. from August 19 through November 11, 2026, and lists April 8, 2026, as the plan adoption or instruction date under the Rule 10b5-1 field.

Key Figures

Proposed shares for sale: 11,431 common shares Aggregate market value: $164,720.71 Shares outstanding: 14,725,646 shares +2 more

5 metrics

Proposed shares for sale 11,431 common shares Atlas Venture Opportunity Fund II, L.P.; approximate sale date November 12, 2026

Aggregate market value $164,720.71 Proposed sale by Atlas Venture Opportunity Fund II, L.P.

Shares outstanding 14,725,646 shares Korro Bio common shares outstanding as reported in the securities information

Prior sale by Atlas Venture Fund XI, L.P. 22,026 common shares Sale dated November 11, 2026

Prior sale by Atlas Venture Opportunity Fund II, L.P. 4,561 common shares Sale dated November 11, 2026

Key Terms

Rule 10b5-1, Private Placement

2 terms

Rule 10b5-1 regulatory

"Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Private Placement financial

"Nature of Acquisition Transaction: Private Placement"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KRRO shares does Atlas Venture Opportunity Fund II plan to sell?

Atlas Venture Opportunity Fund II, L.P. reports a proposed sale of 11,431 common shares, with an aggregate market value of $164,720.71 and an approximate sale date of November 12, 2026.

When did Atlas Venture Opportunity Fund II acquire the KRRO shares, and what Rule 10b5-1 date is listed?

The fund acquired the 11,431 common shares from Korro Bio in a private placement for cash on April 22, 2024. The notice lists April 8, 2026, as the plan adoption or instruction date under the Rule 10b5-1 field.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001885327
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Korro Bio, Inc.
SEC File Number	001-39062
Address of Issuer	60 First Street 2nd Floor, Suite 250 Cambridge MASSACHUSETTS 02141
Phone	6174681999
Name of Person for Whose Account the Securities are To Be Sold	Atlas Venture Opportunity Fund II, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Shareholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 555 California Street 18th Floor San Francisco CA 94104	11431	164720.71	14725646	11/12/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	04/22/2024	Private Placement	Issuer			11431	04/22/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Atlas Venture Fund XI, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	08/19/2026	23584	330159.49
Atlas Venture Fund XI, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	08/26/2026	249	3476.86
Atlas Venture Fund XI, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	09/11/2026	8450	118177.48
Atlas Venture Fund XI, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	09/14/2026	31887	450231.69
Atlas Venture Fund XI, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	11/11/2026	22026	332108.03
Atlas Venture Opportunity Fund II, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	08/19/2026	4884	68372.58
Atlas Venture Opportunity Fund II, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	08/26/2026	51	712.13
Atlas Venture Opportunity Fund II, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	09/11/2026	1750	24474.62
Atlas Venture Opportunity Fund II, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	09/14/2026	6603	93231.72
Atlas Venture Opportunity Fund II, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	11/11/2026	4561	68770.76

144: Remarks and Signature

Remarks
Date of Notice	11/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	04/08/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Ommer Chohan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)